Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects

Diabetes Research and Clinical Practice

Volumn 79, Issue 1, 2008, Pages 79-85

  McKillop, Aine M ^a   Duffy, Nicola A ^a   Lindsay, John R ^b   O'Harte, Finbarr P M ^a   Bell, Patrick M ^b   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Dipeptidyl peptidase IV; Glucagon like peptide 1; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DEGRADATION; DIABETIC PATIENT; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE METABOLISM; HORMONE RESPONSE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; METABOLITE; NON INSULIN DEPENDENT DIABETES MELLITUS;

AGED; ANTIGENS, CD26; BLOOD GLUCOSE; BODY MASS INDEX; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KINETICS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS;

EID: 37549030476     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.08.001     Document Type: Article

References (29)

1. Mentzel S., Dijkman H.B.P.M., Vanson J.P.H.F., Koene R.A.P., and Assmann K.J.M. Organ distribution of aminopeptidase A and dipeptidyl peptidase-IV in normal mice. J. Histochem. Cytochem. 44 (1996) 445-461
2. Gorrell M.D., Gysbers V., and McCaughan G.W. CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes. Scand. J. Immunol. 54 (2001) 249-264
3. Kieffer T.K., Kieffer T.J., and Habener J.F. The glucagon-like peptides. Endocrine Rev. 20 (1999) 876-913
4. Holst J.J., and Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am. J. Physiol. Endocrinol. Metab. 287 (2004) E199-E206
5. Zander M., Madsbad S., Madsen J.L., and Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359 (2002) 824-830
6. Drucker D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diab. Care 26 (2003) 2929-2940
7. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53 (2004) 2181-2189
8. Villanueva-Penacarrillo M.L., Alcantara A.I., Clemente F., Delgado E., and Valverde I. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 37 (1994) 1163-1166
9. Naslund E., King N., Mansten S., Adner N., Holst J.J., Gutniak M., et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br. J. Nutr. 91 (2004) 439-446
10. Kieffer T.J., McIntosh C.H., and Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase. Endocrinology 136 (1996) 3585-3596
11. Mentlein R. Dipeptidyl peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regulat. Pept. 85 (1999) 9-24
12. Knudsen L.B., and Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur. J. Pharmacol. 318 (1996) 429-435
13. Holst J.J., Hansen L., and Deacon C.F. The GLP-1 receptor antagonist, GLP-1(9-36 amide) is a primary product of the intestinal l-cell. Diabetologia 40 (1997) A27
14. Deacon C.F., Knudsen L.B., Madsen K., Wilberg F.C., Jacobsen O., and Holst J.J. Dipeptidylpeptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41 (1998) 271-278
15. Green B.D., Gault V.A., O'Harte F.P.M., and Flatt P.R. Structural modified analogues of glucagon-like peptide 1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr. Pharm. Res. 10 (2004) 3651-3662
16. Green B.D., Mooney M.H., Gault V.A., Irwin N., Bailey C.J., Harriott P., et al. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. J. Endocrinology 180 (2004) 379-388
17. Holst J.J., and Deacon C.F. Inhibition of the activity of dipeptidyl peptidase IV as a treatment of type 2 diabetes. Diabetes 47 (1998) 1663-1670
18. Hildebrandt M., Rose M., Monnikes H., Reutter W., Keller W., and Klapp B.F. Eating disorders: a role for dipeptidyl peptidase IV in nutritional control. Nutrition 17 (2001) 451-454
19. Meneilly G.S., Demuth H.-U., McIntosh C.H.S., and Pederson R.A. Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diab. Med. 17 (2000) 346-350
20. Vilsboll T., Krarup T., Deacon C.F., Madsbad S., and Holst J.J. Reduced postprandial concentration of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50 (2001) 609-613
21. Mannucci E., Pala L., Ciani S., Bardini G., Pezzatini A., Sposato I., et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 48 (2005) 1168-1172
22. Stevens J.F. Determination of glucose by an automatic analyser. Clin. Chim. Acta 32 (1971) 199-201
23. The Diabetes Control and Complications Trial Research Group. Diabetes Control and Complications Trial (DCCT): results of feasibility study. Diab. Care 10 (1987) 1-19
24. Fossati P., Ponti N., Passoni G., Tarenghi G., Meizi d'Eril G.V., and Prencipe L. A step forward in enzymatic measurement of creatinine. Clin. Chem. 40 (1994) 130-137
25. Mannucci E., Ognibene A., Cremasco F., Bardini G., Mencucci A., and Pierazzuoli E. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diab. Care 24 (2001) 489-494
26. Ahren B. What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?. Diabetologia 28 (2005) 605-607
27. Nauck M.A., and El-Ouaghlidi A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia 48 (2005) 608-611
28. McIntosh C.H.S., Demuth H.-U., Pospisilik J.A., and Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?. Regulat. Pept. 128 (2005) 159-165
29. Gault V.A., O'Harte F.P.M., and Flatt P.R. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?. Neuropeptides 37 (2003) 253-263